Total Payments
$207,464
2024 Payments
$26,014
Companies
35
Transactions
207
Medicare Patients
438
Medicare Billing
$103,642
Payment Breakdown by Category
Consulting$139,682 (67.3%)
Travel$26,528 (12.8%)
Research$25,690 (12.4%)
Education$6,214 (3.0%)
Other$5,556 (2.7%)
Food & Beverage$3,794 (1.8%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $139,682 | 89 | 67.3% |
| Travel and Lodging | $26,528 | 29 | 12.8% |
| Unspecified | $25,690 | 20 | 12.4% |
| Education | $6,214 | 4 | 3.0% |
| Honoraria | $5,100 | 3 | 2.5% |
| Food and Beverage | $3,794 | 61 | 1.8% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $456.20 | 1 | 0.2% |
Payments by Type
General
$181,774
187 transactions
Research
$25,690
20 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| GlaxoSmithKline, LLC. | $43,758 | 37 | $0 (2024) |
| AstraZeneca UK Limited | $30,694 | 16 | $0 (2023) |
| Boehringer Ingelheim Finland Ky | $16,975 | 28 | $0 (2018) |
| Takeda Pharmaceuticals U.S.A., Inc. | $15,868 | 12 | $0 (2022) |
| United Therapeutics Corporation | $12,865 | 5 | $0 (2020) |
| E.R. Squibb & Sons, L.L.C. | $12,023 | 15 | $0 (2021) |
| GENZYME CORPORATION | $10,545 | 4 | $0 (2022) |
| Amgen Inc. | $8,490 | 10 | $0 (2024) |
| PFIZER INC. | $8,360 | 3 | $0 (2024) |
| Seagen Inc. | $8,280 | 6 | $0 (2021) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $26,014 | 28 | PFIZER INC. ($8,360) |
| 2023 | $10,851 | 12 | AstraZeneca UK Limited ($5,853) |
| 2022 | $19,988 | 15 | AstraZeneca UK Limited ($6,568) |
| 2021 | $29,436 | 19 | Seagen Inc. ($6,900) |
| 2020 | $33,131 | 21 | GlaxoSmithKline, LLC. ($14,759) |
| 2019 | $16,890 | 19 | GlaxoSmithKline, LLC. ($13,797) |
| 2018 | $27,428 | 29 | United Therapeutics Corporation ($11,432) |
| 2017 | $43,725 | 64 | AstraZeneca UK Limited ($9,819) |
All Payment Transactions
207 individual payment records from CMS Open Payments — Page 1 of 9
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/09/2024 | PFIZER INC. | TUKYSA (Drug) | Consulting Fee | Cash or cash equivalent | $5,060.00 | General |
| Category: Oncology | ||||||
| 12/02/2024 | AstraZeneca Pharmaceuticals LP | — | Consulting Fee | Cash or cash equivalent | $2,870.00 | General |
| 11/02/2024 | Daiichi Sankyo Inc. | ENHERTU (Drug) | Consulting Fee | Cash or cash equivalent | $525.00 | General |
| Category: ONCOLOGY | ||||||
| 11/02/2024 | AstraZeneca Pharmaceuticals LP | TAGRISSO (Drug) | Travel and Lodging | In-kind items and services | $336.55 | General |
| Category: Oncology | ||||||
| 11/02/2024 | AstraZeneca Pharmaceuticals LP | TAGRISSO (Drug) | Food and Beverage | In-kind items and services | $50.07 | General |
| Category: Oncology | ||||||
| 11/02/2024 | AstraZeneca Pharmaceuticals LP | TAGRISSO (Drug) | Travel and Lodging | In-kind items and services | $23.25 | General |
| Category: Oncology | ||||||
| 10/10/2024 | Regeneron Healthcare Solutions, Inc. | LIBTAYO (Biological) | Food and Beverage | In-kind items and services | $28.00 | General |
| Category: ONCOLOGY | ||||||
| 10/10/2024 | Regeneron Healthcare Solutions, Inc. | LIBTAYO (Biological) | Food and Beverage | In-kind items and services | $18.71 | General |
| Category: ONCOLOGY | ||||||
| 10/09/2024 | Regeneron Pharmaceuticals, Inc. | — | Travel and Lodging | In-kind items and services | $89.71 | General |
| 10/08/2024 | Regeneron Pharmaceuticals, Inc. | — | Travel and Lodging | In-kind items and services | $323.68 | General |
| 10/08/2024 | Regeneron Pharmaceuticals, Inc. | — | Travel and Lodging | In-kind items and services | $89.71 | General |
| 10/07/2024 | Regeneron Healthcare Solutions, Inc. | LIBTAYO (Biological) | Food and Beverage | In-kind items and services | $125.01 | General |
| Category: ONCOLOGY | ||||||
| 10/03/2024 | Regeneron Pharmaceuticals, Inc. | — | Travel and Lodging | In-kind items and services | $25.50 | General |
| 09/17/2024 | Amgen Inc. | — | Consulting Fee | Cash or cash equivalent | $2,058.00 | General |
| 09/17/2024 | Amgen Inc. | — | Consulting Fee | Cash or cash equivalent | $1,372.00 | General |
| 09/10/2024 | Novartis Pharmaceuticals Corporation | LUTATHERA (Drug) | Food and Beverage | In-kind items and services | $28.42 | General |
| Category: Oncology | ||||||
| 09/09/2024 | Fosun Pharma USA Inc. | Serplulimab (Biological) | Food and Beverage | In-kind items and services | $181.08 | General |
| Category: Oncology | ||||||
| 08/16/2024 | PFIZER INC. | — | Honoraria | Cash or cash equivalent | $1,100.00 | General |
| 08/14/2024 | AstraZeneca Pharmaceuticals LP | — | Consulting Fee | Cash or cash equivalent | $1,027.50 | General |
| 08/13/2024 | GlaxoSmithKline, LLC. | — | Consulting Fee | Cash or cash equivalent | $2,275.00 | General |
| 06/03/2024 | Genentech USA, Inc. | Alecensa (Biological), Rozlytrek | Food and Beverage | In-kind items and services | $72.05 | General |
| Category: BioOncology | ||||||
| 06/03/2024 | Novartis Pharmaceuticals Corporation | — | Food and Beverage | In-kind items and services | $32.80 | General |
| 05/31/2024 | Amgen Inc. | — | Food and Beverage | In-kind items and services | $42.76 | General |
| 05/24/2024 | PFIZER INC. | — | Honoraria | Cash or cash equivalent | $2,200.00 | General |
| 05/06/2024 | Coherus Biosciences Inc. | — | Honoraria | Cash or cash equivalent | $1,800.00 | General |
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| A TWO-PART OPEN-LABEL RANDOMIZED PHASE IIIII STUDY OF DINUTUXIMAB AND IRINOTECAN VERSUS IRINOTECAN FOR SECOND-LINE TREATMENT OF SUBJECTS WITH RELAPSED OR REFRACTORY SMALL CELL LUNG CANCER | United Therapeutics Corporation | $11,374 | 2 |
| A RANDOMIZED PHASE 3 MULTICENTER OPEN-LABEL STUDY TO COMPARE THE EFFICACY OF TAK-788 AS FIRST-LINE TREATMENT VERSUS PLATINUM-BASED CHEMOTHERAPY IN PATIENTS WITH NON-SMALL CELL LUNG CANCER WITH EGFR EXON 20 INSERTION MUTATIONS | Takeda Pharmaceuticals U.S.A., Inc. | $4,668 | 4 |
| A PHASE 1/2 STUDY OF THE SAFETY, PHARMACOKINETICS, AND ANTI-TUMOR ACTIVITY OF THE ORAL EGFR/HER2 INHIBITOR TAK-788 (AP32788) IN NON-SMALL CELL LUNG CANCER | Takeda Pharmaceuticals U.S.A., Inc. | $4,200 | 3 |
| A PHASE 3 RANDOMIZED OPEN-LABEL STUDY OF BRIGATINIB (ALUNBRIG?) VERSUS ALECTINIB (ALECENSA?) IN ADVANCED ANAPLASTIC LYMPHOMA KINASE-POSITIVE NON-SMALL-CELL LUNG CANCER PATIENTS WHO HAVE PROGRESSED ON CRIZOTINIB (XALKORI?) | Takeda Pharmaceuticals U.S.A., Inc. | $2,450 | 2 |
| A TWO-PART OPEN-LABEL RANDOMIZED PHASE II/III STUDY OF DINUTUXIMAB AND IRINOTECAN VERSUS IRINOTECAN FOR SECOND-LINE TREATMENT OF SUBJECTS WITH RELAPSED OR REFRACTORY SMALL CELL LUNG CANCER | United Therapeutics Corporation | $1,400 | 1 |
| A PHASE 1B/2A PILOT RANDOMIZED STUDY TO EVALUATE THE SAFETY AND TOLERA | GlaxoSmithKline, LLC. | $897.96 | 7 |
| A Trial of AP32788 in Non-Small Cell Lung Cancer | Takeda Pharmaceuticals U.S.A., Inc. | $700.00 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 3 | 117 | 365 | $79,140 | $32,347 |
| 2022 | 3 | 106 | 289 | $65,560 | $26,997 |
| 2021 | 4 | 103 | 284 | $58,450 | $24,389 |
| 2020 | 3 | 112 | 314 | $58,620 | $19,909 |
Total Patients
438
Total Services
1,252
Medicare Billing
$103,642
Procedure Codes
13
All Medicare Procedures & Services
13 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2023 | 66 | 228 | $45,600 | $17,159 | 37.6% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2023 | 39 | 121 | $31,460 | $14,306 | 45.5% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Facility | 2023 | 12 | 16 | $2,080 | $881.76 | 42.4% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2022 | 57 | 209 | $41,800 | $16,775 | 40.1% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2022 | 33 | 64 | $16,640 | $7,739 | 46.5% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Facility | 2022 | 16 | 16 | $7,120 | $2,483 | 34.9% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Facility | 2021 | 47 | 207 | $41,400 | $16,835 | 40.7% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Facility | 2021 | 25 | 38 | $9,880 | $4,757 | 48.2% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Facility | 2021 | 19 | 27 | $3,510 | $1,399 | 39.9% |
| 99204 | New patient outpatient visit, total time 45-59 minutes | Facility | 2021 | 12 | 12 | $3,660 | $1,397 | 38.2% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Facility | 2020 | 56 | 219 | $43,800 | $14,734 | 33.6% |
| 99213 | Established patient office or other outpatient visit, typically 15 minutes | Facility | 2020 | 39 | 76 | $9,880 | $3,338 | 33.8% |
| 99215 | Established patient office or other outpatient, visit typically 40 minutes | Facility | 2020 | 17 | 19 | $4,940 | $1,837 | 37.2% |
About Dr. Martin Edelman, M.D
Dr. Martin Edelman, M.D is a Hematology & Oncology healthcare provider based in Philadelphia, Pennsylvania. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 04/03/2006. The National Provider Identifier (NPI) number assigned to this provider is 1437111978.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Martin Edelman, M.D has received a total of $207,464 in payments from pharmaceutical and medical device companies, with $26,014 received in 2024. These payments were reported across 207 transactions from 35 companies. The most common payment nature is "Consulting Fee" ($139,682).
As a Medicare-enrolled provider, Edelman has provided services to 438 Medicare beneficiaries, totaling 1,252 services with total Medicare billing of $103,642. Data is available for 4 years (2020–2023), covering 13 distinct procedure/service records.
Ad
Practice Information
- Specialty Hematology & Oncology
- Other Specialties Medical Oncology, Medical Oncology
- Location Philadelphia, PA
- Active Since 04/03/2006
- Last Updated 04/09/2018
- Taxonomy Code 207RH0003X
- Entity Type Individual
- NPI Number 1437111978
Products in Payments
- TAGRISSO (Drug) $22,335
- TRADJENTA (Drug) $16,975
- TUKYSA (Drug) $13,340
- UNITUXIN (Drug) $12,832
- LIBTAYO (Biological) $8,352
- OFEV (Drug) $7,947
- OPDIVO (Biological) $6,143
- IMLYGIC (Biological) $4,954
- EXKIVITY (Drug) $3,500
- TEPMETKO (Drug) $2,947
- ALUNBRIG (Drug) $2,450
- SUSTOL (Drug) $2,155
- ZEPZELCA (Drug) $1,956
- Trodelvy (Drug) $760.00
- ENHERTU (Drug) $525.00
- Optune (Device) $500.00
- Avastin (Biological) $248.38
- IMFINZI (Drug) $221.62
- MEKINIST (Drug) $215.03
- Serplulimab (Biological) $181.08
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Hematology & Oncology Doctors in Philadelphia
Shayma Kazmi, Md, MD
Hematology & Oncology — Payments: $715,210
Hematology & Oncology $715,210
Charu Aggarwal, Md, Mph, MD, MPH
Hematology & Oncology — Payments: $510,275
Hematology & Oncology $510,275
Dr. Catherine Lai, M.d., M.p.h, M.D., M.P.H
Hematology & Oncology — Payments: $249,951
Hematology & Oncology $249,951
Keith Pratz, M.d, M.D
Hematology & Oncology — Payments: $175,955
Hematology & Oncology $175,955
David Porter, Md, MD
Hematology & Oncology — Payments: $173,636
Hematology & Oncology $173,636
Marcela Maus, Md, MD
Hematology & Oncology — Payments: $159,783
Hematology & Oncology $159,783